Cargando…

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

Induction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies. The PI3K/Akt pathway is constitutively active in the majority of patients with AML. Given...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xinyu, Su, Yongwei, Madlambayan, Gerard, Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Ma, Jun, Knight, Tristan, Wang, Guan, Wang, Yue, Yang, Jay, Taub, Jeffrey W., Lin, Hai, Ge, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821619/ https://www.ncbi.nlm.nih.gov/pubmed/30819918 http://dx.doi.org/10.3324/haematol.2018.201343

Ejemplares similares

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2020)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
por: Liu, Fangbing, et al.
Publicado: (2020)

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
por: Luedtke, Daniel A., et al.
Publicado: (2020)

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
por: Huegel, Julianne, et al.
Publicado: (2022)

Enhanced Efficacy of 5-Fluorouracil in Combination with a Dual Histone Deacetylase and Phosphatidylinositide 3-Kinase Inhibitor (CUDC-907) in Colorectal Cancer Cells
por: Hamam, Rimi, et al.
Publicado: (2017)

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
por: Hu, Cheng, et al.
Publicado: (2020)

CUDC‐907 blocks multiple pro‐survival signals and abrogates microenvironment protection in CLL
por: Chen, Yixiang, et al.
Publicado: (2018)

Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
por: Al-Mansour, Fares, et al.
Publicado: (2023)

Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia
por: Wang, Tingting, et al.
Publicado: (2019)

Pluripotent stem cell‐based screening identifies CUDC‐907 as an effective compound for restoring the in vitro phenotype of Nakajo‐Nishimura syndrome
por: Kase, Naoya, et al.
Publicado: (2020)

Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis
por: Zhang, Wentian, et al.
Publicado: (2020)

Correction to: Pluripotent Stem Cell-Based Screening Identifies CUDC-907 as an Effective Compound for Restoring the In Vitro Phenotype of Nakajo-Nishimura Syndrome
Publicado: (2022)

Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells
por: Ma, Jun, et al.
Publicado: (2017)

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
por: Oki, Yasuhiro, et al.
Publicado: (2017)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020)

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016)

CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
por: Tu, Tian, et al.
Publicado: (2019)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
por: Jian, Zheng, et al.
Publicado: (2022)

ONC201 induces the unfolded protein response (UPR) in high‐ and low‐grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity
por: Rumman, Marufa, et al.
Publicado: (2021)

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
por: Wu, Shuangshuang, et al.
Publicado: (2022)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition
por: Knight, Tristan E., et al.
Publicado: (2021)

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
por: Xu, Xuelian, et al.
Publicado: (2011)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Maspin expression patterns differ in the invasive versus lepidic growth pattern of pulmonary adenocarcinoma
por: Lonardo, Fulvio, et al.
Publicado: (2014)

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
por: Wang, Guan, et al.
Publicado: (2012)

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
por: Fredly, Hanne, et al.
Publicado: (2013)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Emerging roles for histone deacetylases in age-related muscle atrophy
por: Walsh, Michael E., et al.
Publicado: (2016)

CUDC-101 is a potential target inhibitor for the EGFR-overexpression bladder cancer cells
por: Wang, Zhenxing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ipvt897frgqnlih6r44camk6g